Edition:
India

Aduro Biotech Inc (ADRO.OQ)

ADRO.OQ on NASDAQ Stock Exchange Global Select Market

7.00USD
1:30am IST
Change (% chg)

$0.15 (+2.19%)
Prev Close
$6.85
Open
$6.85
Day's High
$7.12
Day's Low
$6.85
Volume
77,573
Avg. Vol
133,844
52-wk High
$14.00
52-wk Low
$5.85

Select another date:

Tue, Mar 6 2018

BRIEF-Aduro Announces Milestone Achieved Under Merck Collaboration

* ADURO ANNOUNCES MILESTONE ACHIEVED UNDER MERCK COLLABORATION FOR INITIATION OF ANTI-CD27 PHASE I TRIAL IN ADVANCED SOLID TUMORS Source text for Eikon: Further company coverage:

BRIEF-Aduro Biotech Promotes Hans Van Eenennaam In Its Europe Unit

* ADURO BIOTECH APPOINTS HANS VAN EENENNAAM EXECUTIVE VICE PRESIDENT ANTIBODY RESEARCH AND SITE HEAD, ADURO BIOTECH EUROPE Source text for Eikon: Further company coverage:

BRIEF-Aduro Biotech Q4 Loss Per Share $0.34

* ADURO BIOTECH ANNOUNCES FOURTH QUARTER AND FULL YEAR 2017 FINANCIAL RESULTS

BRIEF-Aduro Biotech Announces Management Changes

* ADURO BIOTECH INC - JENNIFER LEW HAS BEEN PROMOTED TO CHIEF FINANCIAL OFFICER

BRIEF-Aduro Biotech Expands Leading Intellectual Property Position In STING Field With Newly Issued Patent

* ADURO BIOTECH EXPANDS LEADING INTELLECTUAL PROPERTY POSITION IN STING FIELD WITH NEWLY ISSUED PATENT Source text for Eikon: Further company coverage:

BRIEF-Aduro Biotech Provides Update On CRS-207 Programs

* COMPANY HAS DETERMINED THAT IT WILL NOT CONTINUE ADVANCEMENT OF CRS-207

BRIEF-Aduro Biotech ‍announces data from preclinical studies with ADU-1604

* Aduro Biotech Inc - ‍announced data from preclinical studies with ADU-1604, company's humanized anti-CTLA-4 monoclonal antibody​

BRIEF-Aduro Biotech reports Q3 loss per share $0.33

* Q3 earnings per share view $-0.36 -- Thomson Reuters I/B/E/S

Select another date: